COMP <GO>
NOVT vs TMO // FORWARD P/E MULTIPLE
Novanta Inc. (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: NOVT 3
— TMO 12
▲ FORWARD P/E MULTIPLE LEADER: TMO
LAST: $145.76 (-3.59%) • MKT CAP: $5.72B
forward-pe
98.8x
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
forward-pe
36.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NOVT VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NOVT | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 44.40% | 41.00% | +3.40 | NOVT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.50% | 9.30% | -2.80 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 51.7x | 30.4x | +21.30 | TMO | /valuation <GO> |
| Free Cash Flow Yield | 0.85% | 2.40% | -1.55 | TMO | /fcf-yield <GO> |
| Operating Margin | 9.60% | 17.40% | -7.80 | TMO | /operating-margins <GO> |
| Net Profit Margin | 5.50% | 15.10% | -9.60 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 3.30% | 3.90% | -0.60 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.30 | 4.50 | +3.80 | NOVT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.70% | +0.20 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.1 | 59.1 | -6.01 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 0.94 | +0.07 | NOVT | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 98.8x | 36.3x | +62.50 | TMO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.72B | $262.22B | -$256.50B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NOVT REV | TMO REV | NOVT GROSS % | TMO GROSS % | NOVT FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $980.6M | $44.56B | 44.4% | 44.0% | $48.4M | $6.29B |
| FY 2024 | $949.2M | $42.88B | 44.4% | 44.0% | $141.3M | $7.27B |
| FY 2023 | $881.7M | $42.86B | 44.0% | 44.0% | $80.4M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NOVT // BETA 1.01
TMO // BETA 0.94